[{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"},{"id":"99134520-51cc-40cf-b215-240e54d8dde8","acronym":"EMR 200066-007","url":"https://clinicaltrials.gov/study/NCT01693068","created_at":"2021-01-17T17:54:22.396Z","updated_at":"2025-02-25T16:02:42.583Z","phase":"Phase 2","brief_title":"Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma","source_id_and_acronym":"NCT01693068 - EMR 200066-007","lead_sponsor":"EMD Serono","biomarkers":" RAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine • pimasertib (AS703026)"],"overall_status":"Completed","enrollment":" Enrollment 194","initiation":"Initiation: 12/05/2012","start_date":" 12/05/2012","primary_txt":" Primary completion: 07/04/2015","primary_completion_date":" 07/04/2015","study_txt":" Completion: 10/24/2016","study_completion_date":" 10/24/2016","last_update_posted":"2018-01-05"},{"id":"80df7b6e-ddde-4bae-9a86-d126eca09c34","acronym":"EMR 200066-006","url":"https://clinicaltrials.gov/study/NCT01390818","created_at":"2021-01-18T05:42:31.509Z","updated_at":"2024-07-02T16:37:24.658Z","phase":"Phase 1","brief_title":"Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01390818 - EMR 200066-006","lead_sponsor":"EMD Serono","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • PTEN • KIT • GNAQ • GNA11","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • PTEN • KIT • GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimasertib (AS703026) • voxtalisib (SAR245409)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2017-03-07"}]